Business Wire

betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All ...

With 51 patients enrolled, data from the long-term follow-up study (LTF-303) show that all patients treated with beti-cel who achieve transfusion independence (TI) remain free from transfusions, with ...
The American Journal of Managed Care

Analysis of Beti-Cel for Severe β-Thalassemia Shows Extensive, Long-term Patient Improvement

A pair of abstracts presented at this year’s 64th American Society of Hematology Annual Meeting and Exposition bear out the significant transfusion-free rate at 3 years following beti-cell ...
Business Wire

Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of ...

All four parent studies are complete, and all patients have transitioned to a long-term follow-up study (LTF-303) SOMERVILLE, Mass.--(BUSINESS WIRE)--Updated data from bluebird bio inc.’s (NASDAQ: ...
Monthly Prescribing Reference

Beti-Cel, a Gene Therapy for Beta-Thalassemia, Gets FDA Panel Support

Credit: Getty Images. Beti-cel is an investigational one-time gene therapy that works by adding functional copies of a modified form of the beta-globin gene into a patient’s own hematopoietic stem ...
Financial Post

betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All ...

As of March 9, 2021, 51 of 63 beti-cel-treated patients across age groups and genotypes spanning a broad range of TDT severity have completed two years of follow-up in the parent study and were ...